Denosumab biosimilar HLX14 versus EU-denosumab in postmenopausal women at high fracture risk: a randomized, double-blind, multicenter phase 3 trial.

Li Xin, Zhiyong Li, Jun Zhang, Qun Xia, Ping Jin, Qingyun Xue, Xin Zheng, Xin Tang, Zhong Yuan, Lin Shen, Peng Duan, Yawei Zhang, Yanan Huo, Bingwu Wang, Zhifeng Cheng, Youliang Cao, Liping Li, Yuhong Zeng, Lizhen Lan, Yibing Lu, Li Mao, Zhan Zhang, Cong Chen, Qingyu Wang, Haoyu Yu, Jing Li, Jun Zhu

DOI: 10.1007/s00198-026-08262-5

На странице источника доступны аннотация, полный текст или сведения о том, где его прочитать.